LOS ANGELES--(BUSINESS WIRE)--Lundin Law PC announces it is investigating claims against Esperion Therapeutics, Inc. (“Esperion” or the “Company”) (Nasdaq: ESPR) concerning possible violations of federal securities laws. The investigation is related to allegations that certain statements issued by Esperion were false and misleading and/or failed to disclose material information regarding the Company’s financial performance.
To participate in this class action lawsuit, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via email at email@example.com.
The investigation concerns whether the Company made misleading statements to investors and/or failed to disclose that the Company had no clear path to approval for ETC-1002, the Company’s lead product candidate designed to lower LDL-cholesterol levels. In addition, the FDA had encouraged the Company to initiate a cardiovascular outcomes trial (“CVOT”) and that completion of a CVOT could be necessary prior to approval of ETC-1002.
No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.